[ad_1]
The COVID-19 vaccine clinical trial intent registration platform will be open for registration on the 11th Image: Central Epidemic Command Center / Provided
Wuhan’s pneumonia epidemic continues to spread globally. The three national companies responsible for research and development of Wuhan’s pneumonia vaccines, including Guoguang, High-end and United Asia Biotech, have entered the first phase of clinical trials and are about to enter the second phase of clinical trials. The Epidemic Central Command Center announced on the 11th the establishment of the “Platform for Registration of Intentions for Clinical Trials of COVID-19 Vaccines”. It is expected to recruit 20,000 willing subjects by November 30, accelerating the rate of acceptance of the vaccine industry. The vaccine industry provides a minimum of 8,000 yuan for nutrition and transportation fees for each subject, attracting many people to sign up as subjects. As of 9 am on the 12th, more than 9,000 people have registered to participate in clinical trials of vaccines.
Wuhan’s national pneumonia vaccine will enter the second phase of clinical trials by the end of the year at the earliest. The government has established a subject recruitment platform for the industry for the first time to speed uptake. In addition to providing subsidies for transportation and nutrition of subjects, the vaccine industry will also provide adverse reactions. A full treatment will be performed and insurance will cover. In terms of subsidies, in the past, subjects in national vaccine clinical trials may receive an average of 2,000 to 3,000 yuan in nutrition and transportation fees each time they go to the hospital to draw blood or vaccinate. The entire clinical trial requires at least 4 to 6 visits, or more. It is estimated that it will start at least 8,000 yuan.
Wu Mingmei, deputy director of the drug group of the Food and Drug Administration of the Ministry of Health and Welfare, noted that the vaccine industry must submit the second phase of clinical trials and approve the review of the Ethics Review Board of hospital research (IRB) before they can be formally selected from the subject’s intent database. And it explains the details of the test, etc., and the test will start with the consent of the subject. Wu Mingmei added that, in general, recruiting subjects cannot participate in advertising. To avoid violating regulations, this time only collect people’s “intentions” in accordance with the “Personal Data Protection Act” and leave the name, gender, date of birth, phone number and mailbox,
The director of the Food and Drug Administration, Wu Xiumei, recalled that it is not recommended that the following six types of people be registered: people with chronic diseases, people with low immune function or diseases of the immune system, people who have undergone major surgery in the last month, people who have undergone cancer treatment or are about to receive treatment, people who are trying to conceive or become pregnant. Women, lactating women. At present, the platform’s registration objective is expected to be at least 20,000, and the conditions are: adults over 20 years of age (except those who are declared by guardianship or auxiliary declarations) and minors under 12 years and under 20 years (with the consent of the legal representatives), You can register from today until November 30.
Wuhan’s national pneumonia vaccine will enter the second phase of clinical trials by the end of the year at the earliest. The government has established a subject recruitment platform for the industry for the first time to accelerate uptake. In addition to providing subsidies for transportation and nutrition of subjects, the vaccine industry will also provide adverse reactions. A full treatment will be performed and insurance will cover. In terms of subsidies, in the past, subjects in national vaccine clinical trials may receive an average of 2,000 to 3,000 yuan in nutrition and transportation fees each time they go to the hospital to draw blood or vaccinate. The entire clinical trial requires at least 4 to 6 visits, or more. It is estimated that it will start with at least 8,000 yuan.
Wuhan’s pneumonia epidemic continues to spread globally. The three national companies responsible for research and development of Wuhan’s pneumonia vaccines, including Guoguang, High-end and United Asia Biotech, have entered the first phase of clinical trials and are about to enter the second phase of clinical trials. The Epidemic Central Command Center announced on the 11th the establishment of the “Platform for Registration of Intentions for Clinical Trials of COVID-19 Vaccines”. It is expected to recruit 20,000 willing subjects by November 30, accelerating the rate of acceptance of the vaccine industry. The vaccine industry provides a minimum of 8,000 yuan for nutrition and transportation fees for each subject, attracting many people to register as subjects. As of 9 am on the 12th, more than 9,000 people have registered to participate in clinical trials of vaccines.
[ad_2]
